(Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating ...
At Liv Hospital, specialists emphasize that stem cell therapy isn’t a one-size-fits-all solution. Instead, it is carefully indicated for specific diseases, patient profiles, and treatment ...
Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster ...
A research team has identified the impact of stem cell infusion timing on the incidence and severity of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation ...
Credit: Getty Images. The goal of HCT is to cure an underlying malignancy or hematologic disorder. The procedure can be performed in an inpatient or outpatient setting. Each setting is associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results